Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.55 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.55 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.55 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | AKT1 | P31749 | 4/20 | 0.50 |
| ▸ | LCK | P06239 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14530477 | 0.96 | MAPK13 (0.53) | MAPK14MAPK13MAPK12MAPK11POLB | |
| SCHEMBL3107346 | 0.88 | POLB (0.47) | MAPK14MAPK13MAPK12MAPK11POLB | |
| SCHEMBL3114122 | 0.88 | KCNA5 (0.46) | MAPK14MAPK13MAPK12MAPK11POLB | |
| SCHEMBL428867 | 0.86 | CYP3A4 (0.56) | MAPTALDH1A1LMNA | |
| SCHEMBL425124 | 0.85 | POLB (0.55) | POLBALDH1A1AKT1LCK | |
| SCHEMBL13759251 | 0.84 | MAPK14 (0.51) | MAPK14MAPK13MAPK12MAPK11POLB | |
| SCHEMBL3116877 | 0.84 | MAPK14 (0.48) | MAPK14MAPK13MAPK12MAPK11AKT1 | |
| SCHEMBL3112262 | 0.82 | MAPK14 (0.46) | MAPK14MAPK13MAPK12MAPK11MAPT | |
| SCHEMBL426838 | 0.82 | MTOR (0.56) | MAPK14MAPK13MAPK12MAPK11MAPT | |
| SCHEMBL428259 | 0.82 | TSHR (0.52) | POLBMAPTAKT1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236795-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-07 | — | — | US | claimed |
| US-20100256132-A1 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2010-10-07 | — | — | US | claimed |
| US-7696202-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2010-04-13 | — | — | US | claimed |
| EP-1819341-A2 | IL-12 MODULATORY COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2007-08-22 | — | — | EP | claimed |
| US-20060223996-A1 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2006-10-05 | — | — | US | claimed |
| WO-2006053227-A2 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2006-05-18 | — | — | WO | claimed |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-8236795-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236795-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236795-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20120021434-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120021434-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20090163708-A1 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2009-06-25 | — | — | US | disclosed |
| EP-1819341-A2 | IL-12 MODULATORY COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2007-08-22 | — | — | EP | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20060223996-A1 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2006-10-05 | — | — | US | disclosed |
| WO-2006053227-A2 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223996-A1 | IL-12 modulatory compounds | IL2, IL4, IFNG | MAPK14 305/4885MAPK13 315/4885MAPK12 51/4885 |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | REL, NFATC1, BCL6 | MAPK14 3031/4885MAPK13 2455/4885MAPK12 1915/4885 |
| US-20090163708-A1 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | IL17A, IL23R, IL2 | MAPK14 160/4885MAPK13 69/4885MAPK12 25/4885 |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | REL, NFATC1, BCL6 | MAPK14 3031/4885MAPK13 2455/4885MAPK12 1915/4885 |
| US-20100256132-A1 | IL-12 MODULATORY COMPOUNDS | IL2, IL4, IFNG | MAPK14 305/4885MAPK13 315/4885MAPK12 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.